BSEGemstone Investments LtdMediumNeutral
Announced Sat, 30 May · 11:31 IST

Submission of Unaudited Financial Results along with Limited Review Report for the quarter ended 31st December 2025

Pat NegativeRevenue Growth 20pctAuditor Mid Year ChangeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹1.68
prior close
₹1.65
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.0-0.6-0.6+0.0-2.4-1.8+0.6-4.2-4.2-4.8-3.6-5.4
Up moveDown movePending
AI summary

Gemstone Investments reported Q3 FY26 standalone revenue of Rs 58.02 lakh, up sharply from Rs 2.39 lakh in Q3 FY25. For the 9-month period, revenue grew to Rs 131.60 lakh from Rs 89.18 lakh. However, profitability collapsed — Q3 posted a loss of Rs 26.80 lakh (vs loss of Rs 11.19 lakh a year ago) and 9-month PAT fell to Rs 1.72 lakh from Rs 23.11 lakh, a ~92.6% decline. Other expenses surged to Rs 88.43 lakh (vs Rs 40.79 lakh YoY), with Rs 9.03 lakh in bad debt written off. The company also issued ~39.36 crore convertible equity warrants on a preferential basis in November 2025, significantly diluting equity. Note 2 reveals that the statutory auditor was critically ill and hospitalized, delaying submission of the Limited Review Report, raising concerns about audit continuity.

Likely market impact

Sharp revenue growth was undermined by a steep profit decline and large expense escalation. The auditor health issue creates governance risk, and the large warrant issuance signals potential equity dilution for existing shareholders.